Semnur Pharmaceuticals, Inc. (“Semnur”), a wholly owned subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. (Nasdaq: DECA) (“SPAC”) announce signing of a letter of intent for a proposed business combination, which provides for a pre-transaction equity value of Semnur of up to $2.0 billion, subject to adjustment based on third-party fairness opinion, with expected cash on hand at closing of up to $40 million depending on the number of SPAC shares th

Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA, EXCEPT AS PERMITTED BY APPLICABLE LAW. As announced on 25 June 2024, Zealand Pharma commenced a directed share offering to institutional and professional investors through an accelerated bookbuilding. Toda

Funding of $1.49 million USD to support the development of KLS-13019 targeting neuroinflammation and mitochondrial dysfunction Kannalife has developed a new class of orally bioavailable drugs to address neurodegenerative and inflammatory diseases by targeting mNCX-1, GPR55 and the NLRP3 inflammasome June 25, 2024 -- Kannalife Sciences, Inc., a pioneering biotech company dedicated to developing small molecule therapeutics targeting inflammation, is pleased to announce it has been awarded funding

June 18, 2024 -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company” or “FOXO”), today announced that it has secured up to $2.8 million in Senior Notes from an institutional investor (“Investor”) to fund the previously announced acquisition of Myrtle Recovery Centers, Inc. as well as provide additional working capital to support the Company’s growth strategy. Mark White, Interim CEO of FOXO, said, “We appreciate the support of this institutional investor, which we believe is further va

Adcytherix Launches with € 30m in Seed Funding to Develop Next Generation Antibody Drug Conjugates Vision is to establish a leading ADC developer to treat high unmet need diseases such as cancer. Founded by the team that founded and sold Emergence Therapeutics to Eli Lilly and Company. Seed round led by Pontifax and includes top-tier life science investors. 11 June 2024: Adcytherix SAS today announced its incorporation and seed funding of € 30 million to develop novel antibody-drug- conjugates (

Financing led by Zimmer Biomet with participation from existing investors Johnson & Johnson Innovation – JJDC, Inc., Gideon Strategic Partners, and HM Capital. Proceeds will support NDA submission and commercial launch of lead candidate, VT-X7, a 7-day treatment for periprosthetic joint infection. June 05, 2024 -- Osteal Therapeutics, Inc. (“Osteal”), a clinical-stage biopharmaceutical company developing a new category of combination drug/device therapies for orthopedic infections, announced to

Founder and lead investor ARCH Venture Partners is joined by NVIDIA’s NVentures, Menlo Ventures, and Madrona Funding accelerates advancement of Vilya's proprietary computational drug design and development platform and its pipeline of novel macrocycles that precisely target disease biology Vilya's foundational technology leverages advanced computational approaches to design novel macrocycles with atomic-level accuracy and enhanced drug-like properties June 04, 2024 -- VILYA, Inc. (Vilya), a bio

Positions company to further leverage strength of platform and advance programs through multiple data readouts and clinical value inflection points Strengthens balance sheet with cash, cash equivalents and short-term investments of $310 million and extends cash runway into 2027 May 22, 2024 -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced th

LIfT BioSciences Awarded Innovate UK Grant to Accelerate Product Development of New IMAN Cell Therapy Variants Groundbreaking in vivo studies will be progressed to explore the impact of IMAN cell therapies in solid tumour and immunology models uniquely available at the Saeb-Parsy Lab at the University of Cambridge 16 May 2024 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech company about to start clinical trials for its first-in-class allogeneic innate cell therapy, toda

May 14, 2024 -- Tavros Therapeutics, Inc., a precision oncology platform company, today announced that the Company has achieved two milestone payments in its collaboration with Vividion Therapeutics, Inc., a wholly owned and independently operated subsidiary of Bayer AG. The payments were triggered by the successful achievement of predefined milestones, underscoring the progress of their strategic collaboration to discover and develop targeted oncology therapies. Eoin McDonnell, Ph.D., CEO and